Avant Diagnostics, Inc. (OTCQB: AVDX) is a medical
technology company that focuses its efforts on the human genome project. This
genetic research continues to delve deeper into identifying variations of
specific genes in the genome. A genome is all of the genes that make up a cell
or organism. It’s basically a recipe book on how to build a human. Variations
in these genes allow scientists to see individual characteristics of disease
states and a person’s propensity for them. Scientists are then able to detect
diseases earlier, thereby providing early treatment, which improves a patient’s
quality of life while preventing disease progression. Avant Diagnostics is a
key contributor to this program by developing its own advanced technology that
identifies early stage ovarian cancer. This early detection can both decrease
medical costs and increase samples while producing faster results.
Avant Diagnostic’s OvaDxⓇ is a microarray-based test that
measures the immune system’s response to early stage ovarian cancer tumor cells
in blood samples. Impressively, this is the market’s first large panel
screening test for the disease. The test has a high sensitivity for all stages
of ovarian cancer and eliminates false negatives and false positives. Plus, the
proteomic panel provides real-time results, speeding up the process towards
treatment if necessary.
To further stand by its aim of creating testing with fast results,
Avant Diagnostics will soon merge with Amarantus Diagnostics, a biotechnology
firm that develops diagnostic tests for neurological diseases. This partnership
has a high potential of delivering diagnosis and monitoring tools for early
detection at an even faster rate.
Not only does OvaDxⓇ deliver fast results, but it cuts
costs in the overall treatment of ovarian cancer for patients and health
centers. According to Current Women’s Health Reviews, late-stage ovarian cancer
treatment could cost at least $210,000 or more. With early detection, a patient
can get affordable treatment for the disease that has not progressed as far as
it could.
Avant Diagnostics intends to make its product available as
soon as possible, so women can be aware of their own ovarian cancer risks. With
accurate and fast results, the company offers women the chance at early
treatment to prevent expensive costs and painful therapy down the road.
For more information, visit the company website at
www.avantdiagnostics.com
Let us hear your thoughts: Avant Diagnostics, Inc. Message
Board
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment